Related Experiment Video
Updated: Aug 18, 2026

Establishment and Characterization of UTI and CAUTI in a Mouse Model
Published on: June 23, 2015
[Perftoran in the endotoxicosis correction in purulent-inflammatory urological diseases]
Abstract:
Perftoran (PF) was used within a complex intensive care of 74 patients with purulent-inflammatory urological diseases and with signs of generalized inflammation. Positive effects were found to be made by PF on the parameters of microcirculation, oxygen status, dynamics of the serum content of cytokines, condition of their balance and immune status, which entailed a regression of endogenous intoxication and arrested the inflammatory lesion in the kidneys. PF cut the intensive care time of patients with complicated urological infection by 4.2+/-0.4 days (p < 0.05). The conclusion is that PF is a novel pathogenetic treatment method applicable to patients with purulent-inflammatory urological diseases.
Related Concept Videos
Drug Elimination by Renal Route: Tubular Secretion
Urinary Tract Infection I: Introduction
Urinary Tract Infection II: Pathophysiology
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Acute Pyelonephritis II: Diagnostic Studies and Management
Kidney Transplant II: Surgical Procedure

